Long-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 11, 2015, Pages F925-F932

  Erdbrugger U ^a   Scheffner, I ^b   Mengel, M ^c   Schwarz, A ^b   Haller, H ^b   Gwinner, W ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Department of Philosophy and Religious Studies   (Canada)

Author keywords

CMV; Long term allograft function; Patient survival; Protocol biopsies

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLOGRAFT; ARTICLE; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; FEMALE; FIBROSING ALVEOLITIS; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; ADVERSE EFFECTS; ATROPHY; BIOPSY; CHI SQUARE DISTRIBUTION; CYTOMEGALOVIRUS INFECTIONS; EPIDEMIOLOGY; FIBROSIS; GERMANY; GLOMERULUS FILTRATION RATE; KAPLAN MEIER METHOD; KIDNEY; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SURGERY; TIME; TREATMENT OUTCOME;

ADULT; ALLOGRAFTS; ATROPHY; BIOPSY; CHI-SQUARE DISTRIBUTION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FIBROSIS; GERMANY; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84949257179     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00317.2015     Document Type: Article

References (29)

1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
2. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 80: 467-477, 2008.
3. Engelmann I, Welte T, Fuhner T, Simon AR, Mattner F, Hoy L, Schulz TF, Gottlieb J. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 45: 47-53, 2009.
4. Erdbruegger U, Scheffner I, Mengel M, Schwarz A, Verhagen W, Haller H, Gwinner W. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant 27: 435-443, 2012.
5. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 338: 1741-1751, 1998.
6. + cell reduction. Am J Transplant 13: 2119-2129, 2013.
7. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 85: 893-898, 2013.
8. Helantera I, Teppo AM, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I. Increased urinary excretion of transforming growth factor-beta(1) in renal transplant recipients during cytomegalovirus infection. Transpl Immunol 15: 217-221, 2006.
9. Helantera I, Kyllonen L, Lautenschlager I, Salmela K, Koskinen P. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 10: 2026-2032, 2010.
10. Inkinen K, Soots A, Krogerus L, Bruggeman C, Ahonen J, Lauten- schlager I. Cytomegalovirus increases collagen synthesis in chronic rejection in the rat. Nephrol Dial Transplant 17: 772-779, 2002.
11. Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients. Transplantation 88: 77-82., 2009.
12. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 8: 975-983, 2008.
13. Lautenschlager I, Soots A, Krogerus L, Inkinen K, Kloover J, Loginov R, Holma K, Kauppinen H, Bruggeman C, Ahonen J. Time-related effects of cytomegalovirus infection on the development of chronic renal allograft rejection in a rat model. Intervirology 42: 279-284, 1999.
14. Leone F, Akl A, Giral M, Dantal J, Blancho G, Soulillou JP, Can- tarovich D. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Transpl Int 23: 897-906, 2010.
15. Le Page AK, Mackie FE, McTaggart SJ, Kennedy S. Cytomegalovirus and Epstein Barr virus serostatus as a predictor of the long term outcome of kidney transplantation. Nephrology (Carlton) 18: 813-819, 2013.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34: 1094-1097, 2002.
17. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5: 218-227, 2005.
18. Rane S, Nada R, Minz M, Sakhuja V, Joshi K. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients. Transplant Proc 44: 713-716, 2012.
19. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation87: 436-444, 2009.
20. Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O. Long-term outcomes of preemptive valganciclovir compared with valacy- clovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 23: 1588-1597, 2012.
21. Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degre M, Fauchald P, Rollag H. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66: 329-337, 2004.
22. San-Juan R, De Dios B, Garcia-Reyne A, Fernandez-Ruiz M, Lum- breras C, Lopez-Medrano F, Morales JM, Hernando S, Folgueira D, Jimenez C, Aguado JM. Limited impact of cytomegalovirus infection in the long-term outcome of renal and liver transplant. J Clin Virol 56: 316-322, 2013.
23. Schwarz A, Gwinner W, Hiss M, Radermacher J, Mengel M, Haller H. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 5: 1992-1996, 2005.
24. Sebekova K, Feber J, Carpenter B, Shaw L, Karnauchow T, Diaz- Mitoma F, Filler G. Tissue viral DNA is associated with chronic allograft nephropathy. Pediatr Transplant 9: 598-603, 2005.
25. Shimamura M, Seleme MC, Guo L, Saunders U, Schoeb TR, George JF, Britt WJ. Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage. Transplantation 95: 48-53, 2013.
26. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10: 464-471, 2010.
27. Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21: 1579-1586, 2010.
28. Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on longterm renal allograft outcomes. Transplantation 90: 412-418, 2010.
29. van Ree RM, de Vries AP, Zelle DM, de Vries LV, Oterdoom LH, Gans RO, Schouten JP, Lems SP, van Son WJ, Bakker SJ. Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients. Med Sci Monit 17: 609-617, 2011.